Histogenics to seek FDA approval for cell therapy despite failed study
September 05, 2018 at 11:56 AM EDT
The company's stock price sunk to an all-time low on Wednesday after it released the trial data.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.